Last reviewed · How we verify

Pyrotinib in combination with Capecitabine. — Competitive Intelligence Brief

Pyrotinib in combination with Capecitabine. (Pyrotinib in combination with Capecitabine.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 3 Tyrosine kinase inhibitor HER2/neu Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pyrotinib in combination with Capecitabine. (Pyrotinib in combination with Capecitabine.) — Jiangsu HengRui Medicine Co., Ltd.. Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, and when combined with Capecitabine, it is used to treat HER2-positive breast cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pyrotinib in combination with Capecitabine. TARGET Pyrotinib in combination with Capecitabine. Jiangsu HengRui Medicine Co., Ltd. phase 3 Tyrosine kinase inhibitor HER2/neu
epirubicin - cyclophosphamide / docetaxel + trastuzumab epirubicin - cyclophosphamide / docetaxel + trastuzumab GBG Forschungs GmbH phase 3 anthracycline antibiotic/alkylating agent/taxane/monoclonal antibody topoisomerase II/DNA/HER2/neu receptor
Trastuzumab SC Trastuzumab SC Dana-Farber Cancer Institute phase 3 HER2/neu receptor antagonist HER2/neu
Pyrotinib, Trastuzumab, Docetaxel Pyrotinib, Trastuzumab, Docetaxel Jiangsu HengRui Medicine Co., Ltd. phase 3 Tyrosine kinase inhibitor, Monoclonal antibody, Taxane HER2/neu receptor, HER2 protein, Microtubules
pyrotinib plus capecitabine pyrotinib plus capecitabine Henan Cancer Hospital phase 3 Tyrosine kinase inhibitor, Antimetabolite HER2/neu, Thymidylate synthase
TQB2440 injection + Trastuzumab + Docetaxel TQB2440 injection + Trastuzumab + Docetaxel Chia Tai Tianqing Pharmaceutical Group Co., Ltd. phase 3 Targeted therapy, monoclonal antibody, chemotherapy PD-1, HER2/neu
Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab Institut de cancérologie Strasbourg Europe phase 3 Taxane + monoclonal antibody Microtubules + HER2/neu receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

  1. Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
  2. Centre Leon Berard · 2 drugs in this class
  3. AB Science · 2 drugs in this class
  4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  5. Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
  6. Angion Biomedica Corp · 1 drug in this class
  7. Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
  8. Chang-Ming Huang, Prof. · 1 drug in this class
  9. Deciphera Pharmaceuticals, LLC · 1 drug in this class
  10. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pyrotinib in combination with Capecitabine. — Competitive Intelligence Brief. https://druglandscape.com/ci/pyrotinib-in-combination-with-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: